Compare Amgen, Inc. (AMGN) vs Southwest Airlines Co (LUV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Southwest Airlines Co — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Southwest Airlines Co trades at $48.06 (market cap $23.67B). The key difference: Amgen, Inc. is far larger — about 8.3× Southwest Airlines Co's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | LUV | |
|---|---|---|
Market Cap | $196.12B | $23.67B |
Sector | Health | Industrials |
52-Week High | $388.16 | $54.80 |
52-Week Low | $271.18 | $29.06 |
Enterprise Value | $241.41B | $26.74B |
Dividend Yield | 2.77% | 1.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Southwest Airlines (LUV) trades at $48.43, down 1.61% today, with a bullish technical signal from moving averages and RSI near oversold levels. The company reported mixed Q1 2026 earnings, missing estimates, but maintains a positive outlook with Q2 2026 EPS expected at $0.52. Recent news highlights sector tailwinds from lower fuel costs and a partnership with AWS to accelerate AI capabilities by 2028.
LUV presents a balanced risk-reward profile with a consensus price target of $52.47, offering ~8% upside. Key opportunities include earnings growth potential and favorable industry dynamics, while risks involve Boeing 737 MAX incidents and volatile fuel prices. Analyst sentiment is mixed, with 42% buy ratings, reflecting cautious optimism amid operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Southwest Airlines Co
Southwest Airlines is the largest domestic carrier in the United States, as measured by the number of originating passengers boarded. Southwest operates over 700 aircraft in an all-Boeing 737 fleet. Despite expanding into longer routes and business travel, the airline still specializes in short-haul leisure flights, using a point-to-point network. Southwest operates a low-cost carrier business model.
Read more on LUV →
